FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz) Planegg-Martinsried, Germany, September 27, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the U.S. Food and ...

Plaque psoriasis, the most common form of psoriasis (about 90 per cent of cases), is a chronic inflammatory autoimmune ...

The company has also reported positive data for PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, and ...

The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ResearchAndMarkets.com's offering. This report provides a ...

The FDA announced that it has accepted the supplemental sNDA for roflumilast foam 0.3% in those with scalp and body psoriasis over 12.

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports ...

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjpBiosimilarity between ...

Question: I have rosacea and it usually occurs on my face. I recently noticed that it has started happening elsewhere on my ...

The FDA has already approved Zoryve cream (0.3% and 0.15%) for plaque psoriasis and atopic dermatitis in adults and children ...

Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ...

A new study utilised data from the UK Biobank to shed light on a potential causal link between psoriasis and lung and breast ...

Struggling with persistent dandruff can lead to scalp psoriasis. Know the key signs and symptoms to help identify this common ...